ArticleJournal of pharmacokinetics and pharmacodynamics2005
Some considerations on the design of population pharmacokinetic studies.
Article in Journal of pharmacokinetics and pharmacodynamics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial.Orphanet journal of rare diseases · 2017Trial
- Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants.Pediatric research · 2016Trial
- Pharmacokinetics and safety of a single intravenous dose of myo-inositol in preterm infants of 23-29 wk.Pediatric research · 2013Trial
- Population pharmacokinetics of lamotrigine in Indian epileptic patients.European journal of clinical pharmacology · 2013Trial
- Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age.Antimicrobial agents and chemotherapy · 2012Trial
- Advances and Further Comparison of Software Tools for Fisher Information Matrix-Based Design Evaluation in Pharmacometrics.Pharmaceutical research · 2026Article
- Population pharmacokinetics of caspofungin in critically ill Chinese children: a prospective observational study.Antimicrobial agents and chemotherapy · 2026Observational
- Therapeutic Drug Monitoring for Precision Dosing of Janus Kinase Inhibitors: Protocol for a Prospective Observational Study.JMIR research protocols · 2025Article
- Optimal sample selection applied to information rich, dense data.Journal of pharmacokinetics and pharmacodynamics · 2024Article
- Population pharmacokinetics of ivermectin for the treatment of scabies in Indigenous Australian children.PLoS neglected tropical diseases · 2020Article
- External evaluation of population pharmacokinetic models for continuous administration of meropenem in critically ill adult patients.European journal of clinical pharmacology · 2020Observational
- Generating Robust and Informative NonclinicalAntimicrobial agents and chemotherapy · 2019Review
- Randomized, double-blinded, controlled non-inferiority trials evaluating the immunogenicity and safety of fractional doses of Yellow Fever vaccines in Kenya and Uganda.Wellcome open research · 2019Article
- Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance.Clinical pharmacokinetics · 2019Review
- Deterministic identifiability of population pharmacokinetic and pharmacokinetic-pharmacodynamic models.Journal of pharmacokinetics and pharmacodynamics · 2017Article
- Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.British journal of clinical pharmacology · 2015Article
- New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients.Pediatric transplantation · 2014Article
- Leveraging physiological data from literature into a pharmacokinetic model to support informative clinical study design in pregnant women.Pharmaceutical research · 2012Article
- Optimal study design for pioglitazone in septic pediatric patients.Journal of pharmacokinetics and pharmacodynamics · 2011Article
- Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling.European journal of clinical pharmacology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal of this manuscript is to introduce a framework for consideration of designs for population pharmacokinetic orpharmacokinetic-pharmacodynamic studies. A standard one compartment pharmacokinetic model with first-order input and elimination is considered. A series of theoretical designs are considered that explore the influence of optimizing the allocation of sampling times, allocating patients to elementary designs, consideration of sparse sampling and unbalanced designs and also the influence of single vs. multiple dose designs. It was found that what appears to be relatively sparse sampling (less blood samples per patient than the number of fixed effects parameters to estimate) can also be highly informative. Overall, it is evident that exploring the population design space can yield many parsimonious designs that are efficient for parameter estimation and that may not otherwise have been considered without the aid of optimal design theory.
Indexed as
Identifiers
16284917What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.